- Details
- Phillip Koo and Evan Yu, discuss the phenotypic expression of PSMA. Phenotypic precision medicine guides physicians in looking at the molecular characteristics of a tumor to identify the optimal personalized treatment for the patient. Drs. Yu and Koo discuss the use of PSMA-PET/CT imaging that may fill the critical gaps in prostate cancer staging and as a biomarker for metabolic concordance or res...
|
- Details
- Brenda Martone and Alicia Morgans discuss the positioning of radium-223 in the treatment of patients with bone-only mCRPC. Brenda emphasizes that radium-223 is approved for symptomatic bone-only disease and that this includes many symptoms including fatigue, loss of appetite, and others that are not limited to bone-related pain. This is approved in a broad population and needs to be considered in...
|
- Details
- Oliver Sartor, MD, joins Charles Ryan, MD in a conversation about the New England Journal of Medicine publication "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer" known as the VISION trial. The VISION Trial is an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with a...
|
- Details
- Alicia Morgans engages with Michael Morris to delve into the rapidly evolving landscape of radiopharmaceuticals in prostate cancer treatment, highlighting the significance of the VISION data and existing therapies like radium-223. Dr. Morris outlines that the abundance of radiopharmaceutical tools is a "good problem to have," emphasizing that these agents are not one-size-fits-all but have unique...
|
- Details
- Charles Ryan interviews Elena Castro and Fernando Lopez-Campos. They delve into their real-world data on the management of metastatic castration-resistant prostate cancer (mCRPC) in Spain, specifically focusing on the impact of early PSA progression on overall survival in patients treated with enzalutamide or abiraterone. Drs. Castro and Lopez-Campos discuss the significance of monitoring PSA leve...
|
- Details
- Bone strengthening agents such as bisphosphonates or the RANKL-targeting antibody denosumab reduced the bone loss associated with androgen deprivation therapy (ADT) and prevent skeletal-related events in castration resistant prostate cancer (CRPC). The use of these agents is recommended in CRPC by many guidelines. The randomized phase III EORTC-1333-GUCG also known as the PEACE-III trial, compares...
|
- Details
- The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D. In...
|
- Details
- Emmanuel Antonarakis joins Charles Ryan highlighting the first randomized study to assess high-dose testosterone as a treatment for metastatic castration-resistant prostate cancer (mCRPC). TRANSFORMER (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance) was led by Dr. Samuel R. Denmeade at Johns Hopkins School of Medicine – Sidney Kim...
|
- Details
- The presence of mutations in DNA damage repair (DDR) genes has been found in up to 30% of men with metastatic castration-resistant prostate cancer (mCRPC). The CARD trial (Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer) where cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling–targeted inhibitor (abiraterone or enz...
|
- Details
- Unequivocal clinical progression (UPC), a worsening of clinical status with or without radiographic progression represents a distinct mode of disease progression in metastatic prostate cancer. It is prognostic and associated with inferior overall survival and post-progression survival. In this conversation with Alicia Morgans, MD, MPH, Arpit Rao, MD highlights rigorous data set from the phase III...
|
